CorMedix derivative suit settlement preliminarily approved; final hearing Sept 23, 2026

CorMedix Inc.

Court granted preliminary approval on July 24, 2026; final settlement hearing set for Sept 23, 2026 in Newark, NJ.
Settlement requires corporate governance reforms maintained for 3.5 years; no monetary payment to stockholders.
Plaintiffs' counsel may seek up to $3.9M in fees; defendants reserve right to oppose.
Claims alleged fiduciary breaches over DefenCath manufacturing deficiencies and delayed FDA approval (2019-2022).
Settlement resolves federal and state derivative actions; securities class action not part of this settlement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.